CellaVision (CEVI.ST) Stock Price

CellaVision Price

OMX·CLOSED
147.20SEK-4.80 (-3.21 %)
Market closed

Over the last 19 years CellaVision grew revenue by 14.8% annually, reaching 758.97 M SEK. Earnings per share have grown at 11.2% per year over the last 17 years. For CellaVision, the net margin of 20.2% is down versus 22.2% a few years ago. At today's price the dividend yield works out to roughly 1.70%. The payout ratio is around 39% of earnings. The dividend has grown at 15.1% per year over the past 13 years. The consensus 12-month price target for CellaVision is 232.56 SEK, about 58.0% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 24% above its 52-week low.

CellaVision stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of CellaVision over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CellaVision stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CellaVision's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

CellaVision Stock Price History
DateCellaVision Price
7/31/2026147.20 SEK
7/30/2026152.00 SEK
7/29/2026152.60 SEK
7/28/2026142.20 SEK
7/27/2026141.80 SEK
7/24/2026140.00 SEK
7/23/2026140.40 SEK
7/22/2026142.20 SEK
7/21/2026144.80 SEK
7/20/2026148.80 SEK
7/17/2026151.00 SEK
7/15/2026135.40 SEK
7/14/2026134.40 SEK
7/13/2026138.40 SEK
7/10/2026138.40 SEK
7/9/2026134.80 SEK
7/8/2026133.40 SEK
7/7/2026136.60 SEK
7/6/2026143.40 SEK
7/3/2026146.40 SEK
7/2/2026142.80 SEK
7/1/2026137.00 SEK
6/30/2026136.20 SEK
6/29/2026135.40 SEK
6/26/2026136.00 SEK
6/25/2026138.80 SEK
6/24/2026136.80 SEK
6/23/2026138.40 SEK
6/22/2026135.20 SEK
6/18/2026137.20 SEK
6/17/2026140.60 SEK
6/16/2026145.60 SEK
6/15/2026151.00 SEK
6/12/2026137.20 SEK
6/11/2026131.40 SEK
6/10/2026127.00 SEK
6/9/2026126.20 SEK
6/8/2026128.40 SEK
6/5/2026126.00 SEK
6/4/2026123.20 SEK
6/3/2026120.80 SEK
6/2/2026120.60 SEK
6/1/2026120.80 SEK
5/29/2026120.60 SEK
5/28/2026119.80 SEK
5/27/2026122.60 SEK
5/26/2026122.20 SEK
5/25/2026124.40 SEK
5/22/2026122.00 SEK
5/21/2026124.40 SEK
5/20/2026124.00 SEK
5/19/2026124.20 SEK
5/18/2026122.80 SEK
5/15/2026123.20 SEK
5/13/2026120.40 SEK
5/12/2026118.60 SEK
5/11/2026120.20 SEK
5/8/2026118.40 SEK
5/7/2026120.40 SEK
5/6/2026121.00 SEK
5/5/2026120.80 SEK
5/4/2026122.60 SEK
4/30/2026121.20 SEK
4/29/2026122.60 SEK
4/28/2026126.40 SEK
4/27/2026121.60 SEK
4/24/2026120.20 SEK
4/23/2026153.20 SEK
4/22/2026154.00 SEK
4/21/2026158.40 SEK
4/20/2026158.80 SEK
4/17/2026161.60 SEK
4/16/2026159.60 SEK
4/15/2026152.00 SEK
4/14/2026150.60 SEK
4/13/2026149.80 SEK
4/10/2026151.00 SEK
4/9/2026149.60 SEK
4/8/2026153.00 SEK
4/7/2026156.20 SEK
4/2/2026153.20 SEK
3/27/2026147.72 SEK
3/26/2026147.57 SEK
3/25/2026147.40 SEK
3/24/2026144.20 SEK
3/23/2026142.13 SEK
3/20/2026145.80 SEK
3/19/2026147.27 SEK
3/17/2026149.36 SEK
3/16/2026148.60 SEK
3/13/2026149.80 SEK
3/12/2026150.81 SEK
3/11/2026156.00 SEK
3/10/2026154.22 SEK
3/9/2026152.80 SEK
3/6/2026153.73 SEK
3/5/2026151.54 SEK
2/26/2026156.46 SEK
2/25/2026150.58 SEK
2/23/2026150.30 SEK
2/20/2026153.98 SEK
2/19/2026156.80 SEK
2/18/2026148.90 SEK
2/17/2026146.20 SEK
2/16/2026150.16 SEK
2/13/2026153.40 SEK
2/12/2026149.72 SEK
2/11/2026154.40 SEK
2/10/2026161.00 SEK
2/9/2026158.61 SEK
2/6/2026158.54 SEK
2/5/2026157.54 SEK
2/4/2026141.37 SEK
2/3/2026142.01 SEK
2/2/2026145.47 SEK
1/30/2026147.31 SEK
1/29/2026150.00 SEK
1/28/2026151.03 SEK
1/27/2026153.07 SEK
1/26/2026153.96 SEK
1/23/2026155.58 SEK
1/22/2026158.24 SEK
1/21/2026154.02 SEK
1/20/2026157.71 SEK
1/19/2026154.57 SEK
1/16/2026158.40 SEK
1/15/2026158.89 SEK
1/14/2026154.80 SEK
1/13/2026157.80 SEK
1/12/2026158.64 SEK
1/9/2026154.20 SEK
1/8/2026154.60 SEK
1/7/2026156.60 SEK
1/5/2026150.81 SEK
1/2/2026153.35 SEK
12/30/2025156.55 SEK
12/29/2025156.40 SEK
12/23/2025155.60 SEK
12/22/2025155.35 SEK
12/19/2025154.27 SEK
12/18/2025154.80 SEK
12/17/2025149.80 SEK
12/16/2025150.53 SEK
12/15/2025150.00 SEK
12/12/2025153.30 SEK
12/11/2025153.96 SEK
12/10/2025152.03 SEK
12/9/2025150.69 SEK
12/8/2025153.25 SEK
12/5/2025155.60 SEK
12/4/2025157.00 SEK
12/3/2025157.00 SEK
12/2/2025161.30 SEK
12/1/2025161.54 SEK
11/28/2025165.77 SEK
11/27/2025166.82 SEK
11/26/2025164.91 SEK
11/25/2025164.21 SEK
11/24/2025157.20 SEK
11/21/2025159.17 SEK
11/20/2025157.56 SEK
11/19/2025154.74 SEK
11/18/2025154.45 SEK
11/17/2025158.40 SEK
11/14/2025159.80 SEK
11/13/2025160.12 SEK
11/12/2025161.40 SEK
11/11/2025160.60 SEK
11/10/2025160.76 SEK
11/7/2025164.64 SEK
11/6/2025160.37 SEK
11/5/2025175.20 SEK
11/4/2025177.66 SEK
11/3/2025187.39 SEK
10/31/2025179.80 SEK
10/30/2025182.17 SEK
10/29/2025186.98 SEK
10/28/2025184.22 SEK
10/27/2025185.74 SEK
10/24/2025188.49 SEK
10/23/2025188.00 SEK
10/22/2025186.45 SEK
10/21/2025180.22 SEK
10/20/2025179.80 SEK
10/17/2025179.10 SEK
10/16/2025181.86 SEK
10/15/2025178.00 SEK
10/14/2025179.26 SEK
10/13/2025177.83 SEK
10/10/2025178.65 SEK
10/9/2025182.30 SEK
10/8/2025181.92 SEK
10/7/2025182.02 SEK
10/6/2025182.55 SEK
10/3/2025176.09 SEK
10/2/2025172.80 SEK
10/1/2025177.61 SEK
9/29/2025175.40 SEK
9/26/2025174.20 SEK
9/25/2025175.60 SEK
9/24/2025175.20 SEK
9/23/2025178.04 SEK
9/22/2025177.48 SEK
9/19/2025178.50 SEK
9/18/2025183.60 SEK
9/17/2025177.66 SEK
9/16/2025180.20 SEK
9/15/2025174.26 SEK
9/12/2025180.05 SEK
9/11/2025180.50 SEK
9/10/2025181.65 SEK
9/9/2025178.93 SEK
9/8/2025170.55 SEK
9/5/2025169.00 SEK
9/4/2025170.40 SEK
9/3/2025170.37 SEK
9/2/2025170.46 SEK
9/1/2025175.14 SEK
8/29/2025174.58 SEK
8/28/2025176.86 SEK
8/27/2025178.02 SEK
8/26/2025178.20 SEK
8/25/2025177.80 SEK
8/22/2025181.17 SEK
8/21/2025172.20 SEK
8/20/2025170.58 SEK
8/19/2025164.79 SEK
8/18/2025157.60 SEK
8/15/2025159.35 SEK
8/14/2025160.70 SEK
8/13/2025165.63 SEK
8/12/2025165.57 SEK
8/11/2025167.28 SEK
8/8/2025165.44 SEK
8/7/2025166.33 SEK
8/6/2025165.96 SEK
Access this data via the Eulerpool API
Get Free API Key

CellaVision Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
565.55 M SEK
162.73 M SEK
125.34 M SEK
Jan 1, 2022
639.34 M SEK
158.27 M SEK
118.34 M SEK
Jan 1, 2023
677.29 M SEK
167.05 M SEK
130.31 M SEK
Jan 1, 2024
723.22 M SEK
177.68 M SEK
140.72 M SEK
Jan 1, 2025
758.97 M SEK
202.07 M SEK
153.08 M SEK
Jan 1, 2026 (e)
775.10 M SEK
200.32 M SEK
141.44 M SEK
Jan 1, 2027 (e)
870.00 M SEK
224.84 M SEK
174.43 M SEK
Jan 1, 2028 (e)
944.73 M SEK
244.16 M SEK
197.81 M SEK

CellaVision Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 10:12 PM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
DIV.SEK
DIV. GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
179.00216.00239.00265.00309.00364.00461.00471.00565.00639.00677.00723.00758.00775.00870.00944.00
5.9220.6710.6510.8816.6017.8026.652.1719.9613.105.956.794.842.2412.268.51
62.5767.1372.8070.9472.1774.1872.8966.4569.3868.5468.3967.3668.4768.4768.4768.47
112.00145.00174.00188.00223.00270.00336.00313.00392.00438.00463.00487.00519.00530.64595.69646.35
25.0042.0065.0067.0090.00111.00127.00110.00162.00158.00167.00177.00202.00200.00224.00244.00
13.9719.4427.2025.2829.1330.4927.5523.3528.6724.7324.6724.4826.6525.8125.7525.85
18.0031.0052.0059.0069.0088.0099.0089.00125.00118.00130.00140.00153.00141.00174.00197.00
200.0072.2267.7413.4616.9527.5412.50-10.1040.45-5.6010.177.699.29-7.8423.4013.22
0.400.501.001.501.501.501.50–0.752.002.252.252.502.753.303.96
–25.00100.0050.00–––––166.6712.50–11.1110.0020.0020.00
23.8523.8523.8523.8523.8523.8523.8523.8523.8523.8523.8723.8523.8523.8523.8523.85
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales CellaVision generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CellaVision retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CellaVision's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares CellaVision has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CellaVision's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

CellaVision stock margins

The CellaVision margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CellaVision. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CellaVision.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
69.37 %
28.77 %
22.16 %
Jan 1, 2022
68.56 %
24.75 %
18.51 %
Jan 1, 2023
68.37 %
24.66 %
19.24 %
Jan 1, 2024
67.35 %
24.57 %
19.46 %
Jan 1, 2025
68.50 %
26.62 %
20.17 %
Jan 1, 2026 (e)
68.50 %
25.84 %
18.25 %
Jan 1, 2027 (e)
68.50 %
25.84 %
20.05 %
Jan 1, 2028 (e)
68.50 %
25.84 %
20.94 %

CellaVision Stock Revenue, EBIT, Earnings per Share

The CellaVision earnings per share therefore indicates how much revenue CellaVision has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
23.71 SEK
6.82 SEK
5.25 SEK
Jan 1, 2022
26.81 SEK
6.64 SEK
4.96 SEK
Jan 1, 2023
28.38 SEK
7.00 SEK
5.46 SEK
Jan 1, 2024
30.32 SEK
7.45 SEK
5.90 SEK
Jan 1, 2025
31.82 SEK
8.47 SEK
6.42 SEK
Jan 1, 2026 (e)
32.50 SEK
8.40 SEK
5.93 SEK
Jan 1, 2027 (e)
36.48 SEK
9.43 SEK
7.31 SEK
Jan 1, 2028 (e)
39.61 SEK
10.24 SEK
8.29 SEK

CellaVision business model & stock analysis

CellaVision AB is an internationally leading company in the development of systems for automated cell imaging and analysis, founded in 1994 in Lund, Sweden.

CellaVision SWOT Analysis

Strengths

1. Technological Expertise: CellaVision AB has built a strong reputation in the market for its advanced technologies in digital microscopy and image analysis.

2. High Quality Products: The company offers high-quality automated hematology analyzers and related software solutions, ensuring accuracy and reliability for its customers.

3. Strong Market Presence: CellaVision AB has established a dominant position in the global hematology market, providing innovative solutions to healthcare institutions worldwide.

Weaknesses

1. Limited Product Portfolio: The company's product portfolio predominantly focuses on hematology analysis, which leaves it vulnerable to market fluctuations and lack of diversification.

2. Dependence on Key Customers: CellaVision AB relies on a few major customers for a significant portion of its revenue, exposing it to potential risks if these relationships deteriorate.

3. Intense Competition: The industry is highly competitive, with several global players vying for market share. CellaVision AB needs to continuously innovate and adapt to maintain its competitive edge.

Opportunities

1. Growing Healthcare Market: The increasing demand for efficient and advanced hematology analyzers presents an opportunity for CellaVision AB to expand its customer base.

2. Emerging Markets: The company can explore untapped markets in developing countries where the adoption of automated hematology analyzers is on the rise.

3. Technological Advancements: Continual advancements in imaging and analysis technologies open doors for CellaVision AB to develop innovative solutions and capture new market segments.

Threats

1. Regulatory Challenges: Changing regulations and compliance requirements in the healthcare industry may pose challenges for CellaVision AB, leading to increased costs and restricted market access.

2. Economic Volatility: Uncertain economic conditions could impact healthcare budgets, potentially reducing the demand for CellaVision AB's products.

3. Technological Obsolescence: Rapid technological advancements could render current products obsolete, necessitating constant investment in research and development to stay ahead.

CellaVision Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

CellaVision historical P/E ratio, EBIT multiple, and P/S ratio

CellaVision annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

CellaVision shares outstanding

The number of shares of CellaVision was 23.85 M in 2025. This indicates how many shares CellaVision is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
23.85 M Stocks
Jan 1, 2022
23.85 M Stocks
Jan 1, 2023
23.87 M Stocks
Jan 1, 2024
23.85 M Stocks
Jan 1, 2025
23.85 M Stocks
Jan 1, 2026 (e)
23.85 M Stocks
Jan 1, 2027 (e)
23.85 M Stocks
Jan 1, 2028 (e)
23.85 M Stocks

CellaVision Dividend History

14 years of dividend payments

YearAnnual DividendYoY ChangePayments
20262.75SEKYTD—1×
Apr 29, 20262.75SEK↑ 10.0%1/1
20252.50SEK↑ 11.1%1×
May 7, 20252.50SEK↑ 11.1%1/1
20242.25SEK 0.0%1×
20232.25SEK↑ 12.5%1×
20222.00SEK↑ 166.7%1×
20210.75SEK↓ 50.0%1×
20191.50SEK 0.0%1×
20181.50SEK 0.0%1×
20171.50SEK 0.0%1×
20161.50SEK↑ 50.0%1×

CellaVision dividend history and estimates

In 2025, CellaVision paid a dividend amounting to 2.50 SEK. Dividend means that CellaVision distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.75 SEK
0.00 SEK
Jan 1, 2022
2.00 SEK
0.00 SEK
Jan 1, 2023
2.25 SEK
0.00 SEK
Jan 1, 2024
2.25 SEK
0.00 SEK
Jan 1, 2025
2.50 SEK
0.00 SEK
Jan 1, 2026
2.75 SEK
0.00 SEK
Jan 1, 2027 (e)
0.00 SEK
3.30 SEK
Jan 1, 2028 (e)
0.00 SEK
3.96 SEK

CellaVision dividend payout ratio

In 2025, CellaVision had a payout ratio of 38.95%. The payout ratio indicates the percentage of the company's profits that CellaVision distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
14.27 %
Jan 1, 2022
40.31 %
Jan 1, 2023
41.21 %
Jan 1, 2024
38.14 %
Jan 1, 2025
38.95 %
Jan 1, 2026 (e)
46.37 %
Jan 1, 2027 (e)
45.12 %
Jan 1, 2028 (e)
47.75 %

Current CellaVision forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.87 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
232.56
Last Price
148.40
Currency
SEK
12M Return Potential
56.71 %
LTM Return
0 %

CellaVision Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/5/20241.59SEK-180.54 MSEK-2023 Q4
2/2/20231.57SEK-190.82 MSEK-2022 Q4
10/26/20221.29SEK-159.35 MSEK-2022 Q3
7/20/20221.52SEK-162.91 MSEK-2022 Q2
5/10/20221.39SEK-157.32 MSEK-2022 Q1
2/4/20221.57SEK-164.43 MSEK-2021 Q4
10/22/20211.10SEK-126.37 MSEK-2021 Q3
7/20/20211.15SEK-135.00 MSEK-2021 Q2
4/28/20211.23SEK-130.43 MSEK-2021 Q1
2/4/20211.37SEK-150.22 MSEK-2020 Q4

EESG©

Eulerpool ESG Scorecard© for the CellaVision stock

50/100
52
Environment
55
Social
42
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions539
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees46
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CellaVision shareholder structure

% Name
2.92834%
Case Kapitalförvaltning AB
Case Kapitalförvaltning AB
1.75444%
Raiffeisen Kapitalanlage-Gesellschaft mbH
Raiffeisen Kapitalanlage-Gesellschaft mbH
1.70760%
Nordea Funds Oy
Nordea Funds Oy
1.67538%
Lansförsäkringar Fondförvaltning AB
Lansförsäkringar Fondförvaltning AB
1.58080%
Amundi Asset Management, SAS
Amundi Asset Management, SAS
1.48837%
Schroder Investment Management (Europe) S.A.
Schroder Investment Management (Europe) S.A.

CellaVision Beneficial Ownership Filings (SEC 13D/G)

Free Float
58.9%
Float Shares
-
Shares Outstanding
-

CellaVision Executives and Management Board

17 members · avg. age 51 · 35 % women

SO

Mr. Simon Oestergaard (53)

President, Chief Executive Officer

6.57 M SEK

Management

MJ

Ms. Monica Joensson (45)

Interim Chief Financial Officer

–
US

Mr. Urban Strindloev (60)

Vice President - Global Sales

–
EB

Ms. Elin Bredberg (46)

Vice President of Human Resources

–
AM

Mr. Adam Morell (48)

Vice President - Devices & Software Division · since 2021

–
CO

Ms. Charlotte Oom (45)

Vice President - Quality, Clinical and Regulatory Affairs

–
JV

Mr. Julien Veyssy (41)

Vice President - Reagents Division

–

Board of Directors

MW

Mr. Mikael Worning (62)

Independent Chairman of the Board

800,000.00 SEK
AJ

Ms. Ann-Charlotte Jarleryd (59)

Independent Director

398,000.00 SEK
CF

Dr. Christer Fahraeus (60)

Director, Founder · since 1998

285,000.00 SEK
LD

Ms. Louise Armstrong- Denby (52)

Independent Director

260,000.00 SEK
SW

Mr. Stefan Wolf (60)

Independent Director

260,000.00 SEK
EH

Mr. Emil Hjalmarsson (36)

Director

–

Frequently asked questions about CellaVision

The business model of CellaVision AB focuses on developing and selling digital solutions for medical laboratories worldwide. CellaVision offers an innovative range of products, including automated digital systems for advanced blood cell analysis and software solutions for efficient lab management. The company's solutions aim to improve lab productivity, quality, and patient care by streamlining workflow processes and enhancing the accuracy of blood cell analysis. CellaVision AB stands as a leading provider in the field of hematology diagnostics, enabling healthcare professionals to make better-informed decisions for optimizing patient outcomes.

CellaVision AB is primarily active in the medical technology industry.

The main competitors of CellaVision AB in the market include Sysmex Corporation, Roche Diagnostics, and Beckman Coulter.

CellaVision AB is a leading global provider of advanced digital solutions for medical microscopy in the field of hematology. Founded in 1994, CellaVision has a rich history in developing and supplying innovative products that revolutionize the analysis of blood and other body fluids. The company's breakthrough technologies enable automated digital microscopy, accelerating and improving the diagnostic workflow in clinical laboratories. CellaVision's solutions offer healthcare professionals increased efficiency, accuracy, and patient safety, ultimately contributing to better healthcare outcomes. With a strong commitment to research and development, CellaVision continues to pioneer advancements in digital hematology, establishing itself as a trusted name in the industry.

CellaVision AB, a renowned company in the stock market, has achieved several significant milestones throughout its journey. These include the development and launch of cutting-edge hematology analyzers, such as the CellaVision DM96 and CellaVision DC-1. The company has also expanded its global presence, establishing strategic partnerships with various leading healthcare organizations worldwide. Furthermore, CellaVision AB has consistently demonstrated its commitment to innovation by continuously enhancing its product portfolio and introducing advanced digital solutions in the field of automated blood and body fluid analysis. With its relentless pursuit of excellence and industry recognition, CellaVision AB stands as a remarkable player in the stock market.

CellaVision AB is primarily present in various countries and regions around the world. With its global reach, the company has established its presence in countries such as Sweden, the United States, and various European and Asian markets. CellaVision AB's extensive global footprint allows it to cater to a diverse customer base and expand its market share internationally.

CellaVision AB represents a set of core values and a corporate philosophy that underpin its operations. The company is committed to excellence, innovation, and customer satisfaction. Through its cutting-edge technologies and solutions, CellaVision aims to revolutionize hematology analysis and improve patient care. With a focus on quality, CellaVision strives to deliver accurate and reliable results, empowering healthcare professionals worldwide. Moreover, the company fosters a culture of collaboration, teamwork, and transparency to drive advancements in the field of medical diagnostics. By embodying these values, CellaVision AB remains dedicated to its mission of transforming healthcare through intelligent automation and efficient laboratory workflows.

Analysts currently set an average price target of 223.72 SEK for the CellaVision stock (median: 232.56 SEK), implying +50.8 % versus the latest price. The consensus is based on 9 analyst ratings.

CellaVision Analyst Price Targets 2026

9 analysts currently rate the CellaVision stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect CellaVision to generate revenue of 775.10 M SEK and earnings per share of 5.93 SEK.

CellaVision Analyst Price Targets 2026

Converted at the current exchange rate, the CellaVision share trades at 13.41 EUR (147.20 SEK).

The CellaVision share (CEVI.ST) is listed on 5 stock exchanges, including: Frankfurt (C26.F), München (C26.MU), London (0MR5.L).

CellaVision AB is a leading provider of digital solutions for automated blood cell analysis. The company, based in Lund, Sweden, was founded in 1994 and now employs over 350 people.

The expected revenue of CellaVision is 775.10 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of CellaVision is 141.44 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CellaVision is currently 24.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CellaVision stock.

The price-to-sales ratio (P/S) of CellaVision is currently 4.53. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CellaVision stock.

The Eulerpool Quality Score for CellaVision is 8/10.

The ISIN of CellaVision is SE0000683484. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of CellaVision is A0NEVD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of CellaVision is CEVI.ST. The ticker symbol is used to trade CellaVision shares on the stock exchange.

Over the past 12 months, CellaVision paid a dividend of 2.50 SEK . This corresponds to a dividend yield of about 1.70 %. For the coming 12 months, CellaVision is expected to pay a dividend of 3.30 SEK.

The current dividend yield of CellaVision is 1.70 %.

CellaVision pays a dividend, distributed in the months of , , , .

CellaVision paid dividends every year for the past 5 years.

For the upcoming 12 months, dividends amounting to 3.30 SEK are expected. This corresponds to a dividend yield of 2.24 %.

CellaVision is assigned to the 'Health' sector.

To receive the latest dividend of CellaVision from amounting to 2.75 SEK, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, CellaVision distributed 2.25 SEK as dividends.

The dividends of CellaVision are distributed in SEK.

All fundamentals and in-depth analysis of CellaVision

Our stock analysis for CellaVision stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CellaVision. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

CellaVision Stock
CellaVision Revenue→
CellaVision Stock
CellaVision Net Income→
CellaVision Stock
CellaVision P/E→
CellaVision Stock
CellaVision P/S→
CellaVision Stock
CellaVision EBIT→
CellaVision Stock
CellaVision Dividend→
CellaVision Stock
CellaVision Directors Dealings→
CellaVision Stock
CellaVision Stocks→
CellaVision Stock
CellaVision Market capitalization→
CellaVision Stock
CellaVision Debt→
CellaVision Stock
CellaVision Liabilities→
CellaVision Stock
CellaVision Equity→
CellaVision Stock
CellaVision AAQS→
CellaVision Stock
CellaVision Employees→
CellaVision Stock
CellaVision ROE→
CellaVision Stock
CellaVision ROA→
CellaVision Stock
CellaVision ROCE→
CellaVision Stock
CellaVision News→
CellaVision Stock
CellaVision Analyst Price Targets→

Health Stocks

Celldex TherapeuticsCell SourceCellectar BiosciencesCell Biotech CoCellectisCelestraCellid CoCelemicsCellSeedCelcuityCellSource CoCEL-SCIAll Stocks A–Z →